Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinsons Disease and Movement Disorders
– ARV-102 was well tolerated in clinical trials for both healthy volunteers…
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety…
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
October 05, 2025 09:00 ET | Source: Spyre Therapeutics, Inc. WALTHAM, Mass.,…
Spyre Therapeutics Announces Grants of Inducement Awards
October 03, 2025 16:05 ET | Source: Spyre Therapeutics, Inc. WALTHAM, Mass.,…
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”),…
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025 16:01 ET | Source: Intellia Therapeutics, Inc. CAMBRIDGE, Mass.,…
Contemporary Care Introduces TMS Therapy to Naples, Florida
Image by Contemporary Care NAPLES, Fla., Oct. 03, 2025 (GLOBE NEWSWIRE) --…
Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 3, 2025,…
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025 16:15 ET | Source: Context Therapeutics Inc. PHILADELPHIA, Oct.…
